Nevro Corp. (NYSE:NVRO) Receives $21.54 Average Target Price from Brokerages

Shares of Nevro Corp. (NYSE:NVROGet Free Report) have received an average rating of “Hold” from the thirteen research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $21.54.

A number of research firms have recently issued reports on NVRO. Canaccord Genuity Group reissued a “hold” rating and issued a $23.00 price target on shares of Nevro in a research report on Thursday, December 21st. StockNews.com raised shares of Nevro from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. Robert W. Baird dropped their price target on shares of Nevro from $23.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, February 22nd. Citigroup lowered their price objective on shares of Nevro from $18.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 3rd. Finally, Oppenheimer downgraded shares of Nevro from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 22nd.

Get Our Latest Research Report on NVRO

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quarry LP raised its stake in shares of Nevro by 174.3% in the second quarter. Quarry LP now owns 1,012 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 643 shares during the last quarter. UBS Group AG lifted its position in shares of Nevro by 206.3% during the fourth quarter. UBS Group AG now owns 1,219 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 821 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Nevro by 26.8% during the third quarter. Tower Research Capital LLC TRC now owns 3,162 shares of the medical equipment provider’s stock worth $61,000 after purchasing an additional 668 shares in the last quarter. Assetmark Inc. lifted its position in shares of Nevro by 30.4% during the fourth quarter. Assetmark Inc. now owns 3,131 shares of the medical equipment provider’s stock worth $67,000 after purchasing an additional 730 shares in the last quarter. Finally, Counterpoint Mutual Funds LLC acquired a new position in shares of Nevro during the third quarter worth approximately $132,000. Institutional investors and hedge funds own 95.52% of the company’s stock.

Nevro Stock Performance

Shares of NVRO opened at $13.23 on Friday. Nevro has a one year low of $12.34 and a one year high of $39.67. The company has a 50-day moving average of $14.90 and a two-hundred day moving average of $17.01. The stock has a market cap of $481.57 million, a price-to-earnings ratio of -5.15 and a beta of 0.89. The company has a debt-to-equity ratio of 0.72, a current ratio of 6.37 and a quick ratio of 4.94.

Nevro (NYSE:NVROGet Free Report) last announced its earnings results on Wednesday, February 21st. The medical equipment provider reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.35. Nevro had a negative net margin of 21.69% and a negative return on equity of 30.22%. The company had revenue of $116.18 million during the quarter, compared to analysts’ expectations of $115.93 million. On average, equities research analysts expect that Nevro will post -2.54 earnings per share for the current year.

Nevro Company Profile

(Get Free Report

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.

See Also

Analyst Recommendations for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.